| Tuesday October 15, 2013 |
| 13:00 | Registration |
|
| 14:00 | Social Programme |
|
| 16:45 | Welcome Address |
|
| Chair |
Dr Takaaki MIURA
(CHUGAI PHARMACEUTICAL, Kanagawa, Japan) |
| 17:00 | KN01 - Biophysical Methods and Fragment Based Drug Discovery: Targeting Protein-Protein Interactions in Cell Regulatory Systems |
Prof. Sir Tom BLUNDELL
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom) |
| 18:00 | Welcome Reception |
|
| Wednesday October 16, 2013 |
| 08:30 | Registration |
|
| 1st Session - Biophysical Characterisation |
|
| Chair |
Dr Johannes OTTL
(NOVARTIS INSTITUTE OF BIOMEDICAL RESEARCH, Basel, Switzerland) |
| 09:00 | PL01 - Binding of Drug Substances to Molecular Targets Investigated by Biophysical Methods |
Dr Michael HENNIG
(F. HOFFMANN-LA ROCHE LTD., Villigen, Switzerland) |
| 09:40 | PL02 - Enabling GPCR Drug Discovery Through Structural and Biophysical Insights |
Dr Rob COOKE
(HEPTARES, Hertfordshire, United Kingdom) |
| 10:20 | Coffee Break |
|
| 10:50 | OC01 - Biophysical Investigations of the Synergistic Activities of Antimicrobial Peptides: New Strategies to Fight Multiresistance |
Prof. Burkhard BECHINGER
(UNIVERSITY OF STRASBOURG, Strasbourg, France) |
| 11:15 | OC02 - X-Ray Crystallography, Kinetic Target-Guided Synthesis and NMR to Unravel the Mode of Action of Insulin Degrading Enzyme Modulators |
Prof. Rebecca DEPREZ-POULAIN
(UNIVERSITY OF LILLE, Lille, France) |
| 11:40 | PL03 - Biophysics to Drive Lead Discovery |
Dr Matthias FRECH
(MERCK, Darmstadt, Germany) |
| 12:20 | Lunch and Networking |
|
| 2nd Session - Mechanistic Analysis |
|
| Chair |
Prof. Helena DANIELSON
(UPPSALA UNIVERSITY, Uppsala, Sweden) |
| 14:00 | PL04 - Protein Methyltransferase Inhibitors as Personalised Cancer Therapeutics: DOT1L and EPZ-5676 |
Dr Ann BORIACK-SJODIN
(EPIZYME, Cambridge, United States) |
| 14:40 | PL05 - Investing in Knowledge: Combining Biophysical Data in Fragment-Based Drug Discovery |
Dr Glyn WILLIAMS
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom) |
| 15:20 | OC03 - Residence and Recognition Time and their Use for Structure Kinetic Relationships and for Judging Efficacy of Lead Series |
Dr Markku HÄMÄLÄINEN
(GE HEALTHCARE BIO-SCIENCES, Uppsala, Sweden) |
| 15:45 | OC04 - Pharmacokinetics and the Drug-Target Residence Time Concept |
Dr Göran DAHL
(ASTRAZENECA, Mölndal, Sweden) |
| 16:10 | Coffee Break |
|
| 16:45 | OC05 - Bringing Light into Antibody Binding Characteristics in Crude Extracts by Means of FCCS |
Dr Frank BECKER
(INTANA BIOSCIENCE GMBH, Planegg, Germany) |
| 17:10 | PL06 - Can we Use Kinetics and Thermodynamics to Guide Drug Discovery? |
Dr Geoff HOLDGATE
(ASTRAZENECA, Macclesfield, United Kingdom) |
| Chair |
Dr Geoff HOLDGATE
(ASTRAZENECA, Macclesfield, United Kingdom) |
| 17:50 | KN02 - Molecular Mechanism of Action (MMOA) in Drug Discovery |
Dr David SWINNEY
(IRND3, Mountain View, United States) |
| 20:00 | Entertainment (optional & subject to prior registration) |
|
| Thursday October 17, 2013 |
| 3rd Session - Emerging Technologies |
|
| Chair |
Dr Matthias FRECH
(MERCK, Darmstadt, Germany) |
| 09:00 | PL07 - Label-Free, Immobilisation-Free Interaction Studies Using Microscale Thermophoresis |
Dr Stefan DUHR
(NANOTEMPER, Munich, Germany) |
| 09:40 | PL08 - Backscattering Interferometry: An Enabling Drug Development Technology |
Dr Darryl BORNHOP
(VANDERBILT UNIVERSITY, Nashville, United States) |
| 10:20 | OC06 - Detection and Analysis of Proteins with an Electro-Switchable DNA Chip |
Dr Ralf STRASSER
(DYNAMIC BIOSENSORS GMBH, Martinsried, Germany) |
| 10:45 | Coffee Break |
|
| 11:15 | OC07 - Binding Rate Constants Measured on Microliter Volume Using On-Chip Temperature Modulation and Fluorescence Lock-In Detection |
Dr Charlie GOSSE
(CNRS, Marcoussis, France) |
| 11:40 | OC08 - CRYO-TEM: The Way to Answer Real Biological Questions through Unraveling the 3D Mechanistics of Protein |
Dr Thomas WOHLFARTH
(FEI, Eindhoven/Acht, The Netherlands) |
| 12:05 | PL09 - Towards Personalised Cancer Medicine with New NMR Tools to Probe Small GTPase Proteins |
Dr Chris MARSHALL
(UNIVERSITY OF TORONTO, Toronto, Canada) |
| 12:45 | Lunch and Networking |
|
| 14:25 | Poster Session |
|
| 15:55 | Coffee Break |
|
| 16:25 | Round-table discussion on hot topics, emerging trends, and new techniques & approaches; sharing of experience and questions from the audience to a panel of experts |
|
| Moderator |
Dr Glyn WILLIAMS
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom) |
| 17:10 | Poster Prizes |
|
| Chair |
Dr Michael HENNIG
(F. HOFFMANN-LA ROCHE LTD., Villigen, Switzerland) |
| 17:25 | KN03 - Combining X-Ray Crystallography and Single-Molecule Methods to Probe Antibiotic Inhibition of Translation |
Prof. Jamie CATE
(UNIVERSITY OF CALIFORNIA, Berkeley, United States) |
| 20:00 | Conference Dinner (optional & subject to prior registration) |
|
| Friday October 18, 2013 |
| 4th Session - Biophysical Methods for Identifying Hits and Leads |
|
| Chair |
Dr Herbert NAR
(BOEHRINGER INGELHEIM, Biberach, Germany) |
| 09:00 | PL10 - Application of SPR Biosensors Throughout the Drug Discovery Process |
Prof. Helena DANIELSON
(UPPSALA UNIVERSITY, Uppsala, Sweden) |
| 09:40 | PL11 - Finding Active Ligands to kRAS Using Solution State NMR |
Dr Till MAURER
(GENENTECH, South San Francisco, United States) |
| 10:20 | Coffee Break |
|
| 10:50 | OC09 - Identification and Validation of Small Molecule Inhibitors of G Protein Beta 1 Gamma 2 |
Dr Preeti BAKRANIA
(MRC TECHNOLOGY, London, United Kingdom) |
| 11:15 | OC10 - Fragments at UCB: Implementation of Non-Covalent Mass Spectrometry and 19F NMR as Orthogonal Screening Techniques |
Dr Hannah MAPLE
(UCB, Slough, United Kingdom) |
| 11:40 | PL12 - Biophysics in Pharmaceutical Lead Discovery |
Dr Johannes OTTL
(NOVARTIS INSTITUTE OF BIOMEDICAL RESEARCH, Basel, Switzerland) |
| 12:20 | Closing Remarks and Departure |
|
